Meta-analysis: Intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease

F. Fabrizi, V. Dixit, M. Magnini, A. Elli, Paul Martin

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: Dialysis patients have suboptimal response towards hepatitis B virus (HBV) vaccine and intradermal hepatitis B virus vaccination has been used to improve the response rate; however, its efficacy remains unclear. Design: Meta-analysis of controlled trials comparing intradermal vs. intramuscular vaccine against HBV among chronic kidney disease patients. Identification: Twelve studies involving 640 unique patients were included if they had controlled design, intervention and control group patients received intradermal or intramuscular vaccine against HBV, respectively. Patients were followed for a minimum of 7 months after the first vaccine dose. Main outcome measures: The odds ratio of failure to respond to HBV vaccine among patients who received vaccine by intradermal vs. intramuscular route was the end point of interest. It was calculated at completion of HBV vaccination and over follow-up. Results: Pooling of study results demonstrated a decreased risk of failure to respond to HBV vaccine among patients who were vaccinated by intradermal vs. intramuscular route (pooled odds ratio at completion of vaccine protocol: 0.36; 95° CI: 0.21-0.62; test of study heterogeneity, P = 0.089). This difference did not occur over follow-up (6-60 months after completing vaccine schedule; pooled odds ratio: 1.1; 95% CI: 0.47-2.5). Conclusions: Dialysis patients show higher seroprotection after intradermal than intramuscular vaccination schedules; this was not apparent over follow-up. Further studies are warranted to assess if the higher seroprotection rates obtained by intradermal route translates into reduced incidence of de novo HBV virus among chronic kidney disease patients.

Original languageEnglish
Pages (from-to)497-506
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume24
Issue number3
DOIs
StatePublished - Aug 1 2006
Externally publishedYes

Fingerprint

Chronic Renal Insufficiency
Hepatitis B virus
Meta-Analysis
Vaccination
Vaccines
Hepatitis B Vaccines
Odds Ratio
Dialysis
Appointments and Schedules
Outcome Assessment (Health Care)
Viruses
Control Groups
Incidence

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Meta-analysis : Intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. / Fabrizi, F.; Dixit, V.; Magnini, M.; Elli, A.; Martin, Paul.

In: Alimentary Pharmacology and Therapeutics, Vol. 24, No. 3, 01.08.2006, p. 497-506.

Research output: Contribution to journalArticle

@article{0d331337fa9b4862b66be0b64213be4a,
title = "Meta-analysis: Intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease",
abstract = "Background: Dialysis patients have suboptimal response towards hepatitis B virus (HBV) vaccine and intradermal hepatitis B virus vaccination has been used to improve the response rate; however, its efficacy remains unclear. Design: Meta-analysis of controlled trials comparing intradermal vs. intramuscular vaccine against HBV among chronic kidney disease patients. Identification: Twelve studies involving 640 unique patients were included if they had controlled design, intervention and control group patients received intradermal or intramuscular vaccine against HBV, respectively. Patients were followed for a minimum of 7 months after the first vaccine dose. Main outcome measures: The odds ratio of failure to respond to HBV vaccine among patients who received vaccine by intradermal vs. intramuscular route was the end point of interest. It was calculated at completion of HBV vaccination and over follow-up. Results: Pooling of study results demonstrated a decreased risk of failure to respond to HBV vaccine among patients who were vaccinated by intradermal vs. intramuscular route (pooled odds ratio at completion of vaccine protocol: 0.36; 95° CI: 0.21-0.62; test of study heterogeneity, P = 0.089). This difference did not occur over follow-up (6-60 months after completing vaccine schedule; pooled odds ratio: 1.1; 95{\%} CI: 0.47-2.5). Conclusions: Dialysis patients show higher seroprotection after intradermal than intramuscular vaccination schedules; this was not apparent over follow-up. Further studies are warranted to assess if the higher seroprotection rates obtained by intradermal route translates into reduced incidence of de novo HBV virus among chronic kidney disease patients.",
author = "F. Fabrizi and V. Dixit and M. Magnini and A. Elli and Paul Martin",
year = "2006",
month = "8",
day = "1",
doi = "10.1111/j.1365-2036.2006.03002.x",
language = "English",
volume = "24",
pages = "497--506",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Meta-analysis

T2 - Intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease

AU - Fabrizi, F.

AU - Dixit, V.

AU - Magnini, M.

AU - Elli, A.

AU - Martin, Paul

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Background: Dialysis patients have suboptimal response towards hepatitis B virus (HBV) vaccine and intradermal hepatitis B virus vaccination has been used to improve the response rate; however, its efficacy remains unclear. Design: Meta-analysis of controlled trials comparing intradermal vs. intramuscular vaccine against HBV among chronic kidney disease patients. Identification: Twelve studies involving 640 unique patients were included if they had controlled design, intervention and control group patients received intradermal or intramuscular vaccine against HBV, respectively. Patients were followed for a minimum of 7 months after the first vaccine dose. Main outcome measures: The odds ratio of failure to respond to HBV vaccine among patients who received vaccine by intradermal vs. intramuscular route was the end point of interest. It was calculated at completion of HBV vaccination and over follow-up. Results: Pooling of study results demonstrated a decreased risk of failure to respond to HBV vaccine among patients who were vaccinated by intradermal vs. intramuscular route (pooled odds ratio at completion of vaccine protocol: 0.36; 95° CI: 0.21-0.62; test of study heterogeneity, P = 0.089). This difference did not occur over follow-up (6-60 months after completing vaccine schedule; pooled odds ratio: 1.1; 95% CI: 0.47-2.5). Conclusions: Dialysis patients show higher seroprotection after intradermal than intramuscular vaccination schedules; this was not apparent over follow-up. Further studies are warranted to assess if the higher seroprotection rates obtained by intradermal route translates into reduced incidence of de novo HBV virus among chronic kidney disease patients.

AB - Background: Dialysis patients have suboptimal response towards hepatitis B virus (HBV) vaccine and intradermal hepatitis B virus vaccination has been used to improve the response rate; however, its efficacy remains unclear. Design: Meta-analysis of controlled trials comparing intradermal vs. intramuscular vaccine against HBV among chronic kidney disease patients. Identification: Twelve studies involving 640 unique patients were included if they had controlled design, intervention and control group patients received intradermal or intramuscular vaccine against HBV, respectively. Patients were followed for a minimum of 7 months after the first vaccine dose. Main outcome measures: The odds ratio of failure to respond to HBV vaccine among patients who received vaccine by intradermal vs. intramuscular route was the end point of interest. It was calculated at completion of HBV vaccination and over follow-up. Results: Pooling of study results demonstrated a decreased risk of failure to respond to HBV vaccine among patients who were vaccinated by intradermal vs. intramuscular route (pooled odds ratio at completion of vaccine protocol: 0.36; 95° CI: 0.21-0.62; test of study heterogeneity, P = 0.089). This difference did not occur over follow-up (6-60 months after completing vaccine schedule; pooled odds ratio: 1.1; 95% CI: 0.47-2.5). Conclusions: Dialysis patients show higher seroprotection after intradermal than intramuscular vaccination schedules; this was not apparent over follow-up. Further studies are warranted to assess if the higher seroprotection rates obtained by intradermal route translates into reduced incidence of de novo HBV virus among chronic kidney disease patients.

UR - http://www.scopus.com/inward/record.url?scp=33745897315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745897315&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2006.03002.x

DO - 10.1111/j.1365-2036.2006.03002.x

M3 - Article

C2 - 16886915

AN - SCOPUS:33745897315

VL - 24

SP - 497

EP - 506

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 3

ER -